Aliskiren combined with losartan in type 2 diabetes and nephropathy.

By H. Parving, F. Persson, J. Lewis, E. Lewis, N. Hollenberg. New England Journal of Medicine, 2008

983 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, background): “A study reported that combination therapy with an RA system inhibitor enhanced the proteinuria-reducing effects [747].”
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, background): “To date, available evidence shows that, when used alone, aliskiren lowers SBP and DBP in younger and elderly hypertensive patients [428]; that it has a greater antihypertensive effect when given in combinationwith a thiazide diuretic, a blocker of the RAS at other sites, or a calcium antagonist [429”
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. (2012, background): “One 6-month phase 2 study of Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) reported a further reduction of albuminuria with the addition of the direct renin inhibitor aliskiren to losartan in patients with type 2 diabetes and microalbuminuria.(114) A phase 3 study, Aliskiren Trial i”